October 30, 2024
Title: The Burden of Time: MS Treatment and Socio-Economic Impact Reduction
Wednesday, October 30, 2024
9:00AM EDT | 1:00PM UTC | 2:00PM CEST
Click here for time zone conversion.
Description
This webinar will start with a brief 5-minute introduction of the study participants, followed by a 15-minute presentation outlining the study’s objectives, methodology, and key findings. Afterward, a 40-minute moderated Q&A session will allow for discussion and reflection on the insights. The webinar will present a novel study that explores the impact of Multiple Sclerosis (MS) on patients’ health and overall well-being, highlighting the importance of early access to disease-modifying treatments (DMTs) with convenient administration. MS not only affects physical health but also has a significant impact on mental wellbeing, family life, employment, and the lives of caregivers. These combined effects create a substantial socioeconomic burden.
Early treatment access has been linked to reducing this burden by improving:
- Daily activity performance
- Social participation
- Childcare capabilities
- Relationships
- Employment status
The study findings emphasize the need for policies that recognize the broader value of treatments and support patient choice in treatment and care options. Following the presentation, the panel will provide reflections on the findings from the perspectives of policymakers, the MS community, and the pharmaceutical industry. Topics will include:
- The impact of early access to DMTs on patient health and overall well-being
- Socioeconomic benefits of improved ability to work for both People Living with MS (PLwMS) and caregivers
- Policy recommendations to address gaps in treatment access and well-being management for PLwMS
Learning Objectives
- Understand the impact of MS on patients, caregivers, healthcare systems, and the associated socioeconomic burden.
- Learn how timely access to effective treatments can reduce the burden on PLwMS, caregivers, and society.
- Explore policy options that enhance patient involvement in decision-making and support timely access to treatments that impact their well-being and participation in society.
Moderator:
Tim Wilsdon, MSc, Vice President, Life Sciences, Charles River Associates, London, England, UK
Speakers:
Artes Haderi, MSc, Principal, Life Sciences, Charles River Associates, London, England, UK
Christos Andriopoulos, BSc., MSc., MBA, Vice President, Global Marketing Lead, Multiple Sclerosis Portfolio, Merck KGaA, Athens, Greece
Georgina Carr, MSc - International Development and Poverty, Chief Executive, The Neurological Alliance, Leeds, England, UK
Steven Simoens, MSc, PhD, Professor of Health Economics, KU Leuven, Leuven, Belgium
Brought to you by: Merck KGaA, Darmstadt, Germany
Please note: On the day of the scheduled webinar, the first 1000 registered participants will be accepted into the webinar. For those who are unable to attend, or would like to review the webinar at a later date, the full-length webinar recording will be made available at the ISPOR Educational Webinar Series webpage approximately 2 days after the scheduled Webinar.
Reservations are on a first-come, first-served basis.